Gatifloxacin


Concise Prescribing Info
Indications/Uses
Bacterial conjunctivitis.
Dosage/Direction for Use
Adult : Ophth As 0.3% soln: Instill 1 drop 2 hrly into affected eye(s) while awake (up to 8 times/day) for the 1st 2 days then reduce to 1 drop 4 times/day while awake for the next 5 days.
Dosage Details
Ophthalmic
Bacterial conjunctivitis
Adult: As 0.3% soln: Instill 1 drop 2 hrly into affected eye(s) while awake (up to 8 times daily) for the 1st 2 days then reduce to 1 drop 4 times daily while awake for the next 5 days.
Child: ≥1 yr Same as adult dose.
Contraindications
Known hypersensitivity to gatifloxacin, other quinolones.
Special Precautions
Medication should not to be introduced into the anterior chamber of the eye. Pregnancy and lactation.
Adverse Reactions
Conjunctival irritation, increased lacrimation, keratitis, papillary conjunctivitis, chemosis, conjunctival haemorrhage, ocular dryness and redness, ocular discharge/irritation/pain, eyelid oedema, headache, reduced visual acuity, and taste disturbance.
Potentially Fatal: Hypersensitivity reactions including anaphylaxis; fungal or bacterial superinfection.
Patient Counseling Information
Contact lenses should not be worn during treatment. Avoid contamination of the applicator tip w/ material from the eye, fingers or other sources.
MonitoringParameters
Monitor signs of infection. Slit-lamp biomicroscopy and fluorescein staining may be necessary for careful monitoring.
Drug Interactions
Additive effect w/ drugs that prolong QT interval e.g. antiarrhythmic agents (amiodarone, quinidine, sotalol), arsenic trioxide, cisapride, chlorpromazine, droperidol, mefloquine, dolasetron, mesoridazine, moxifloxacin, pimozide, tacrolimus, pentamidine, thioridazine, ziprasidone. Increased risk of blood glucose disturbances w/ drugs that alter blood glucose concentrations (e.g. antidiabetics). Systemic admin may elevate plasma concentrations of theophylline, interfere caffeine metabolism, enhance effects of oral anticoagulant (warfarin and its derivatives), and transient elevations in serum creatinine w/ ciclosporin.
Action
Description: Gatifloxacin is a fluoroquinolone antibacterial which acts by inhibiting DNA synthesis in susceptible organisms via inhibition of both DNA gyrase (essential for bacterial reproduction) and topoisomerase IV (essential during bacterial cell division).
Pharmacokinetics:
Absorption: Not measurable.
Distribution: Widely distributed into body tissues. Plasma protein binding: Approx 20%.
Metabolism: Limited metabolism.
Excretion: Via urine mainly as unchanged drug w/ <1% as metabolites; faeces (approx 5% as unchanged drug). Elimination half-life: 7-14 hr.
Chemical Structure

Chemical Structure Image
Gatifloxacin

Source: National Center for Biotechnology Information. PubChem Database. Gatifloxacin, CID=5379, https://pubchem.ncbi.nlm.nih.gov/compound/Gatifloxacin (accessed on Jan. 22, 2020)

Storage
Store between 15-25°C. Protect from freezing.
References
Anon. Gatifloxacin (EENT). AHFS Clinical Drug Information [online]. Bethesda, MD. American Society of Health-System Pharmacists, Inc. https://www.ahfscdi.com. Accessed 17/07/2014.

Anon. Gatifloxacin. Lexicomp Online. Hudson, Ohio. Wolters Kluwer Clinical Drug Information, Inc. https://online.lexi.com. Accessed 17/07/2014.

Buckingham R (ed). Gatifloxacin. Martindale: The Complete Drug Reference [online]. London. Pharmaceutical Press. https://www.medicinescomplete.com. Accessed 17/07/2014.

Wickersham RM. Gatifloxacin Ophthalmic. Facts and Comparisons [online]. St. Louis, MO. Wolters Kluwer Clinical Drug Information, Inc. https://www.wolterskluwercdi.com/facts-comparisons-online/. Accessed 17/07/2014.

Zymaxid Solution/Drops (Allergan Inc.). DailyMed. Source: U.S. National Library of Medicine. https://dailymed.nlm.nih.gov/dailymed/. Accessed 17/07/2014.

Disclaimer: This information is independently developed by MIMS based on Gatifloxacin from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to MIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, MIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2020 MIMS. All rights reserved. Powered by MIMS.com
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in